Back to top

A cabotegravir PrEP implant that could last a year

A team of researchers presented continuing progress with an implant that can protect

HIV-negative people against the virus for an entire year.

They reported on the development of an in-situ forming implant (ISFI). It’s still early days, with research in mice, but it’s good news about future options for HIV prevention. 

With this report, Rahima Benhabbour, PhD, of the University of North Carolina at Chapel Hill, and colleagues showed an ability to more than double the effective time of the implant, from 180 days (roughly six months) to 390 days. 

At the same time, the research showed an ability to reduce the length of the drug’s PK tail (the amount of time that a drug remains at detectable levels in the body). This would help cut the risk of developing drug resistance when the medication is stopped.

The team used cabotegravir (CAB), a long-acting medication from ViiV Healthcare. ViiV already has a CAB-based drug on the market for HIV prevention (PrEP), Apretude. (PrEP stands for pre-exposure prophylaxis.) But while Apretude consists of a long-acting injection that is given every two months, the researchers called the CAB-based ISFI “ultra-long-acting.” Nice.

The study demonstrated, in part, the ability to see the pocket of cabotegravir in the body and how the drug is released. The ISFI is both biodegradable and removable. It was “well-tolerated and showed minimal to moderate signs of local inflammation and none to minimal systemic inflammation,” researchers said. The teeny implant was placed into the mice with a syringe.

CAB is also used as part of a complete HIV regimen (brand name Cabenuva) given every two months with another antiviral medication, rilpivirine. Like Apretude, both medications in Cabenuva are given as long-acting injectables. 

Benhabbour and colleagues published the study results in the October 10 issue of Journal of Controlled Release. 

To read more, GO TO doi.org/10.1016/j.jconrel.2025.114166 and poz.com/article/cabotegravir-prep-implant-might-prevent-hiv-year.

Extra, Extra!

Are you interested in “Anti-science bills hit statehouses, stripping away public health protections build over a century” from STAT? Videos on how to “Join the PrEP Revolution: How to Fight for HIV Prevention” from POZ? Or see how “More Europeans are dying from HIV now than 15 years ago,” from Aidsmap? Then sign up for the Global Health Watch from AVAC. Those three articles were featured in the October 24 issue. 

According to AVAC, “Global Health Watch is a weekly newsletter breaking down critical developments in U.S. policies and their impact on global health. Tailored for our partners in the U.S. and around the world, this resource offers a concise analysis of the week’s events, supporting advocates to respond to threats, challenges and opportunities in this critical period of change in global health.” 

AVAC also offers PxWire, featuring reports that focus on drug development and The Choice Agenda (TCA), a global listserv of HIV news devoted to community members and providers. Check out TCA’s recorded webinars. GO TO avac.org/signup.

Allowing people with HIV in European clinical trials

“People living with HIV have long faced exclusion from clinical research unrelated to HIV, limiting access to potentially life-saving treatments and leaving critical knowledge gaps about safety and efficacy of innovative treatment and prevention for them,” says the European AIDS Treatment Group (EATG). 

In response, the EATG organized an online consultation meeting. The group convened October 7 as part

of its project called The Belong. “Ongoing since 2022, Belong seeks to ensure that people living with HIV are meaningfully represented in clinical trials across all disease areas, particularly conditions that disproportionately affect them.”

To read more, GO TO eatg.org/news/eatg-drives-progress-on-inclusion-of-people-living-with-hiv-in-clinical-trials. To read EATG’s three-and-a-half page report of the virtual get-together, GO TO eatg.org/wp-content/uploads/2025/10/belong-online-consultation-report.pdf.

Sexual and reproductive health series

The Lancet in October launched a series focusing on sexual and reproductive health. The British medical journal invited globally-renowned HIV medical providers and researchers, led by editors Kenneth Mayer, MD, of Fenway Health Center in Boston, and Linda-Gail Beker, MD, of the Desmond Tutu HIV Centre in Cape Town, South Africa, to write five papers on these topics:

Global trends in sexual and reproductive health—Andrew Grulich, of the Kirby Institute, University of New South Wales 

Innovations in contraception—Deborah Anderson, of the Boston University School of Medicine

Advances in HIV/STI prevention and care—Remco Peters, of the World Health Organization

Costs and funding of SRH interventions—Gesine Meyer-Rath and Lise Jamieson, of HE2RO, in Johannesburg, South Africa) 

Building integrated programs—Ken Mayer, of Fenway Health, Harvard University Center for AIDS Research and The Lancet)

There is also a comment, A rights-based imperative for young women, by Nomonde Ngema. Free partial access to the papers is available. GO TO thelancet.com/series-do/sexual-reproductive-health.

HIV awareness and prevention among Black African women in England

A study in the London-based Women’s Health journal reported on how social conditions affect Black African women when it comes to HIV.

“There have been impressive advancements made in preventing and treating HIV. However, the impacts have not been experienced equally across demographics in England,” wrote Nicola Jones of the Terrence Higgins Trust in London and colleagues. “African-born persons, in particular women of Black African ethnicity, continue to be disproportionately affected by HIV. HIV prevention campaigns have often overlooked social, cultural and structural factors that shape access to HIV prevention.”

Speaking with 23 women in focus groups and one-on-one interviews, Jones and colleagues found three recurring themes, the report said:

Enduring fear of HIV rooted in past lived experiences: Fear of HIV derives from traumatic lived experiences, which have shaped trust in health care services in England and limited the acceptance of information about HIV treatment, such as U=U (Undetectable = Untransmittable).

Responsibility for HIV transmission and prevention: There was a low perception of HIV acquisition risk, shaped by personal circumstances and stigmatizing beliefs. [The women] acknowledging they may be at risk of HIV acquisition attributed this to the behavior of their male partners. 

Motivation to change attitudes and reduce stigma: Participating in this study provided a safe space for women to share their experiences of HIV, ask questions and learn new information, revealing focus groups as an effective method of raising awareness and reducing stigma.

In their conclusion, they note that, “Multiple factors shape the understanding of HIV and uptake of HIV prevention among women of African and Caribbean heritage. Local, community-specific and participatory HIV prevention interventions are needed to understand and respond to these factors.”

The study is available free online (open access). To read Breaking barriers: A qualitative study exploring the social and cultural factors that influence HIV awareness and uptake of HIV prevention among women of African and Caribbean heritage in England, GO TO doi.org/10.1177/17455057251385798. Breaking barriers was published online October 22.

Gilead puts the kabash on generic Biktarvy

Biktarvy has received an extended lease on life. The drug’s maker, Gilead Sciences, announced in October it had reached an agreement in a patent dispute with three generic drug manufacturers. Lupin Ltd., Cipla Ltd. and Laurus Labs Ltd. have agreed to delay any generic version of Biktarvy until April 1, 2036. Settlement came after the generic makers filed drug applications with the FDA. Gilead had previously projected that the company would lose exclusive rights to market Biktarvy in the U.S. in 2033.   —Rick Guasco